Back to results
US 12,399,186 B2Granted
Method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction
AssigneeSphingotec GmbH
InventorAndreas Bergmann
Life of this patent
Estimating the term…
Abstract
A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.
Claims57
A method comprising:
- receiving a first sample comprising bodily fluid obtained from a subject and an antibody wherein said antibody has an amino acid sequence which is identical to an antibody produced by a process comprising:
- fusing activated B-cells from a mammal previously immunized with a peptide comprising the sequence of Pro-Enkephalin or a fragment thereof, or with a conjugate of said peptide and a carrier protein, with cells of a myeloma cell line and culturing the resulting cells,
- screening said cultures of said fused cells and selecting IgG antibodies that bind to Pro-Enkephalin or a fragment thereof, and
- receiving a second sample of bodily fluid obtained from said subject and an antibody wherein said antibody has an amino acid sequence which is identical to an antibody produced by a process comprising:
- fusing activated B-cells from a mammal previously immunized with a peptide comprising the sequence of Pro-Enkephalin or a fragment thereof, or with a conjugate of said peptide and a carrier protein, with cells of a myeloma cell line and culturing the resulting cells,
- screening said cultures of said fused cells and selecting IgG antibodies that bind to Pro-Enkephalin or a fragment thereof, and
- wherein the second sample is received after the first sample;
- wherein the level of bound Pro-Enkephalin or fragments thereof of at least 5 amino acids in the first sample is lower than a level of Pro-Enkephalin or fragments thereof of at least 5 amino acids in the second sample, wherein said Pro-Enkephalin or fragment thereof is one or more of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10 or SEQ ID No. 11,
- the method additionally comprising treating the subject with a therapeutically effective amount of hyaluronic acid or renal replacement therapy.
6 more elements
A method comprising:
- receiving a first sample comprising bodily fluid obtained from a subject suffering from kidney dysfunction and an antibody wherein said antibody has an amino acid sequence which is identical to an antibody produced by a process comprising:
- fusing activated B-cells from a mammal previously immunized with a peptide comprising the sequence of Pro-Enkephalin or a fragment thereof, or with a conjugate of said peptide and a carrier protein, with cells of a myeloma cell line and culturing the resulting cells,
- screening said cultures of said fused cells and selecting IgG antibodies that bind to Pro-Enkephalin or a fragment thereof, and
- receiving a second sample of bodily fluid obtained from said subject and a antibody wherein said antibody has an amino acid sequence which is identical to an antibody produced by a process comprising:
- fusing activated B-cells from a mammal previously immunized with a peptide comprising the sequence of Pro-Enkephalin or a fragment thereof, or with a conjugate of said peptide and a carrier protein, with cells of a myeloma cell line and culturing the resulting cells,
- screening said cultures of said fused cells and selecting IgG antibodies that bind to Pro-Enkephalin or a fragment thereof,
- and wherein the second sample is received after the first sample;
- wherein the level of bound Pro-Enkephalin or fragments thereof of at least 5 amino acids in the first sample is lower than a level of Pro-Enkephalin or fragments thereof of at least 5 amino acids in the second sample,
- wherein said Pro-Enkephalin or fragment thereof is one or more of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10 or SEQ ID No. 11.
6 more elements
A method comprising:
- receiving a sample comprising bodily fluid obtained from a subject suspected of suffering from kidney dysfunction and an antibody bound to Pro-Enkephalin or fragments thereof of at least 5 amino acids,
- wherein the amount of bound Pro-Enkephalin or fragments thereof of at least 5 amino acids to said binder is greater than 80 pmol MR-Pro-Enkephalin (MRPENK)/L, and
- wherein said antibody has an amino acid sequence which is identical to an antibody produced by a process comprising:
- fusing activated B-cells from a mammal previously immunized with a peptide comprising the sequence of MR Pro-Enkephalin or a fragment thereof, or with a conjugate of said peptide and a carrier protein, with cells of a myeloma cell line and culturing the resulting cells,
- screening said cultures of said fused cells and selecting IgG antibodies that bind to Pro-Enkephalin or a fragment thereof.
2 more elements
A method comprising:
- receiving a sample comprising bodily fluid obtained from a subject suffering from kidney dysfunction and an antibody bound to Pro-Enkephalin or fragments thereof of at least 5 amino acids,
- wherein the amount of bound Pro-Enkephalin or fragments thereof of at least 5 amino acids to said antibody is greater than 80 pmol MR-Pro-Enkephalin (MRPENK)/L, and
- wherein said antibody has an amino acid sequence which is identical to an antibody produced by a process comprising:
- fusing activated B-cells from a mammal previously immunized with a peptide comprising the sequence of Pro-Enkephalin or a fragment thereof, or with a conjugate of said peptide and a carrier protein, with cells of a myeloma cell line and culturing the resulting cells,
- screening said cultures of said fused cells and selecting IgG antibodies that bind to Pro-Enkephalin or a fragment thereof.
2 more elements
Dependencies are inferred from the claim text.